Call Us: (356) 99212 212 - Mail az@anthiazammit.coml

Pharmaceutical Law.

AnthiaZammit Legal / Services / Pharmaceutical Law

Pharmaceutical law in Malta

Malta is the European Union’s smallest Member State and has implemented the EU medicines and medical devices regimes. The principal regulatory authority to ensure the quality safety, and efficacy of medicines is the Superintendent of Public Health, which is the Licensing Authority for the purposes of the Medicines Act.

The Medicines Authority is a body corporate having a separate and distinct legal personality and its functions are delegated to it by the Licensing Authority. It is responsible for assisting and advising the Licensing Authority on any matter relating to the regulation of medicinal products and pharmaceutical activities, as well as establishing licensing and marketing procedures.

The Medicines Authority is headed by a Chief Executive Officer. The Chief Executive Officer is responsible for the overall management and performance of the Medicines Authority including the management of its day-to-day operations. The Medicines Authority has established several directorates and appoints its own officers and employees.

In Malta, to date, medical devices are regulated and authorised by the Malta Competition and Consumer Affairs Authority (MCCAA), although medical devices are planned to be regulated by the Licensing Authority and Medicines Authority in the future.

Legislation–medicines and medical devices

‘Medicinal products are defined and regulated by the Medicines Act (Chapter 458 of the Laws of Malta) and its subsidiary legislation. Medical devices are regulated by the Product Safety Act (Chapter 427 of the Laws of Malta), the Active Implantable Medical Devices  Regulations (SL 427.10 of the Laws of Malta), the In Vitro Diagnostic Medical Devices Regulations (SL 427.16 of the Laws of Malta), and the Medical Devices Regulations (SL 427.44 of the Laws of Malta).

Malta’s pharmaceutical industry

Malta has the second largest pharmaceutical trade balance per capita in the European Union (€614 million in 2016), the tenth in total, and was the EU’s fastest growing pharmaceutical exporter between 2001 and 2016 with an unprecedented increase of 45 per cent. More than 30 established international pharmaceutical brand names operate in Malta, including several US mega-cap corporations.

In terms of the latest industry developments, in 2019, Aurobindo Pharma (Malta) Limited announced the company will invest in oncology research and set up a highly specialised new oncology laboratory in Malta to test oncology medicines destined for the EU and African markets. Aurobindo Pharma, the tenth-largest generic company by sales globally, has been established in Malta for the past 13 years and now employs 150 people.

Companies must adhere to EU requirements in manufacturing, licensing and distribution of pharmaceuticals, active pharmaceutical ingredients and medical devices, and most companies also receive US Food and Drug Administration (USFDA) accreditation.

The pharmaceutical industry has evolved considerably as Malta was able to leverage foreign investment, especially with English being an official language, and developed a strong reputation in manufacturing, batch-release to the EU market, day-one product launches, good engineering expertise, and favourable economic growth.

The Chamber of Commerce, Enterprise, and Industry based in Valletta represents  the pharmaceutical industry in Malta through three sections, namely: the Healthcare Business Section, the Professional Community Lead Pharmacists Business Section, and the Pharmaceutical Manufacturers Business Section. The pharmaceutical manufacturers established their stakeholder group in 2003, before Malta’s EU accession, to lobby their interests during the transposition of EU legislation.

The Chamber of Commerce members include active pharmaceutical ingredient (API) manufacturers, finished dosage form manufacturers, repackaging and labelling companies, wholesale dealers, brokers, and pharmacists.

AnthiaZammit Legal is a member of the Chamber of Commerce, Enterprise, and Industry and formerly served as Legal Counsel to the Healthcare Business Section.

  • Handling of policy and regulatory matters before the European Commission, European agencies and national regulatory authorities.
  • Advice on regulatory compliance with Pharmaceutical Law (medicines legislation) requirements, including product liability, importer and wholesale dealer’s licenses, issues raised by regulations on orphan medicines, paediatrics medicines and advanced therapies, pharmacy licenses (human and veterinary), pharmacy management, internet pharmacies, parallel importation, parallel distribution, packaging and labelling, as well as manufacture (GMP) and distribution (GDP) certification.
  • Advice and assistance in the process of attaining marketing authorisations of medicinal products for human use in European Member States (through national, decentralised or mutual recognition procedures) and from the European Medicines Agency and European Commission through the centralised procedure.
  • Advice on post-market obligations including pharmacovigilance, advertising of medicinal products, information to patients, data protection and classification of medicines.
  • Advice on pharmaceutical pricing issues
  • Advice on the application of the Roche-Bolar exemption in generic drug development
  • Advice on legal, regulatory and public policy issues concerning nanotechnology
  • Counsel on development of personalised medicine therapies and assessment of the legal implications of pharmacogenomics and pharmacogenetics
  • Advice regarding the regulatory framework for medical devices
  • Advice on compliance with the European chemicals law regime (REACH)
  • Advice on European Intellectual Property Rights enforcement and Customs regulation
  • Assistance in patent registration, trademark registration, the European Community Trademark, designs and copyright
  • Counsel on hospital and clinic licensure and certification, healthcare services quality-control, resource-allocation and patients’ rights
  • Assistance in fulfilment of obligations under Occupational Health and Safety law, including the drafting of health and safety policies, advice on compliance with legislation and judicial representation.
  • Assistance in public procurement of medical supplies including advice on European Procurement law and the handling of public contract and tender processes through pre-qualification, selection, negotiation and award
  • Risk Management and Policy Impact Assessment including review of promotional and marketing materials and sales practices, product development strategy and review of regulatory compliance operations to assess compliance to the regulatory authority’s standards
  • Dispute resolution and judicial representation in medical negligence and medical malpractice claims
  • Negotiation and drafting of corporate and commercial agreements

Why Malta?

Strong industry presence

As a member state of the European Union and the euro zone, Malta demonstrates its commitment in providing tailor-made support to its pharmaceutical and life sciences industries – comprising licensed wholesale distributors, importers, re-packagers and manufacturers of finished dosage forms, including non sterile solid dosage forms (tablets and capsules), active pharmaceutical ingredients (APIs), medical gases and medical devices. The total value of Malta’s pharmaceutical exports in 2010 exceeded €208 million ($275 million).

The presence of renowned corporations such as Actavis, Watson, Siegfried, Medichem and Baxter are a testament to Malta’s success in providing the ideal business environment for the launch of pharmaceuticals and medical devices into the European, U.S., North African and Middle Eastern markets.  Operating in an increasingly globalised industry, these companies benefit from the fact that English is an official language of Malta

The Malta Life Sciences Park comprises 10,000m² of built laboratory space and 3,500m² of business facilities for lease to biotechnology and pharmaceutical companies. The Malta Life Sciences Park was inaugurated in 2014 at a cost of €38 million ($50 million) financed by the Government of Malta, Malta Enterprise which develops business promotion and foreign direct investment in compliance with European state aid rules, and the European Regional Development Fund (ERDF). The ERDF finances programmes between the European Commission and national and regional authorities in EU member states to strengthen economic, social and territorial cohesion in the European Union. 

The European Union funds collaborative research projects to support R&D and innovation which improves human health such as the Innovative Medicines Initiative (IMI) which is a public-private partnership between the European Commission, and the European pharmaceutical industry. 

In 2021, Regulation (EU) 2021/2085 establishing the joint undertakings under Horizon Europe established joint undertakings as public–private partnerships under the Horizon Europe programme, as provided in Article 187 of the Treaty on the Functioning of the European Union.  

The Innovative Health Initiative (IHI) facilitates the translation of scientific knowledge into health research and innovation for a competitive European health industry. It covers research and innovation for prevention, diagnostics, treatment, and management of diseases, targeting unmet public health needs. The initiative promotes the objectives of the industrial strategy for EuropeEurope’s Beating Cancer Plan, and the Pharmaceutical Strategy for Europe.

The laws regulating medicinal products for human use, medical devices and chemicals in Malta are fully harmonised with the relevant European Union law regime. Malta grants Good Manufacturing Practice (EU GMP) and Good Distribution Practice (EU GDP) certification through its regulatory authorities.  As an EU member state, Malta is a party to Mutual Recognition Agreements (MRAs) for Good Manufacturing Practice (GMP) with Switzerland, Australia, New Zealand, Canada and Japan.Several manufacturing plants and facilities in Malta successfully undergo U.S. Food and Drug Administration (FDA) inspections.  In December 2011, the U.S. Food and Drug Administration (FDA), and the European Medicines Agency (EMA), committed to further collaboration in Good Manufacturing Practice (GMP) inspection programs for human and veterinary pharmaceutical products.

Malta’s national competent authority engages in harmonisation of medicines regulation via the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), and joined the Pharmaceutical Inspection Cooperation/Scheme (PIC/S) which is an international organisation of pharmaceutical manufacturing inspectorates from 39 countries.

Malta’s national competent authority accepts applications as Reference Member State in the Decentralised Procedure in accordance with Article 10 of Directive 2001/83/EC, as amended.

A company registered in Malta for the carrying out of the sale, purchase and distribution of medicinal products within the EU, or the importation of medicinal products from a non-EU member state into the EU, may contract out all physical handling activity to a European licensed wholesale dealer or importer.

A business operating as a virtual wholesale dealer or virtual importer is required to hold a valid wholesale dealers license or importer’s license issued by Malta’s national competent authority and comply with good distribution practice (GDP) or good manufacturing practice (GMP) standards under EU law.

Back to Top